IDEXX Laboratories (IDXX) investor relations material

Innovation-driven growth strategy

• Focus on expanding diagnostics, software, and AI to address a $45B global pet testing opportunity, with a multi-decade R&D investment exceeding $2.5B over 21 years driving new platforms and menu expansion.

• Recent launches include inVue Dx for cytology, IDEXX MultiCue Dx, proBNP for cardiac testing, and continuous menu additions to Catalyst, all designed for seamless integration and workflow efficiency.

• Cancer Dx is expanding from a single test to a multi-cancer panel, adding mast cell tumor and hemangiosarcoma detection, aiming to cover 40% of canine cancers at a $15 price point.

• AI and software are embedded across diagnostics and imaging, enabling personalized protocols, workflow automation, and higher diagnostic utilization.

• Commercial expansion targets international growth, leveraging a proven commercial playbook, tailored products, and direct sales models in key markets like Spain, France, South Korea, and Canada.

Sector and market trends

• Pet population and clinical visits remain above pre-pandemic levels, with aging pets, breed shifts, and longer lifespans driving higher care needs and diagnostic spend.

• Preventive care and wellness plans are gaining traction, especially among younger generations, with wellness blood testing inclusion rising sharply when bundled in plans.

• Owners increasingly view pets as family, prioritizing their health even during economic uncertainty, supporting durable sector growth.

• Diagnostic utilization remains a significant growth lever, with substantial opportunity to increase bloodwork inclusion in clinical and wellness visits.

• Early adopters of new diagnostic innovations experience higher clinical and diagnostic revenue growth compared to peers.

Financial performance and guidance

• CAG diagnostic recurring revenues have grown 10%+ annually over five years, with high margins, strong customer loyalty (NPS >50), and 10–13% U.S. and 13–16% international growth.

• Long-term guidance targets 8.5%-11% annual recurring revenue growth, with innovation and utilization as primary drivers, and clinical visit recovery as an additional tailwind.

• Software and diagnostic services are expected to grow 15%+ annually, amplified by cloud migration and integration with diagnostics.

• Operating margins are projected to exceed 32% in 2026, with targeted annual expansion of 50–100 bps and long-term EPS growth potential of 15%+.

• Free cash flow per share has compounded at 25% since 2015, with over $6B cumulative free cash flow, ongoing share buybacks, and high returns on invested capital (50% in 2025).